Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | FT522 |
Trade Name | |
Synonyms | FT-522|FT 522 |
Drug Descriptions |
FT522 comprises allogeneic iPSC-derived NK cells engineered to express a chimeric antigen receptor (CAR) targeting CD19, a CD16 Fc receptor, a recombinant fusion of IL-15 and IL-15RF, and an alloimmune defense receptor (ADR) targeting TNFRSF9 (4-1BB), and to eliminate expression of CD38, which potentially enhances antibody-dependent cellular cytotoxicity (ADCC) and antitumor immune response (Blood (2024) 144 (Supplement 1): 6543, NCI Drug Dictionary). |
DrugClasses | CD19 Immune Cell Therapy 64 |
CAS Registry Number | NA |
NCIT ID | C202279 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Bendamustine + FT522 + Rituximab | Bendamustine FT522 Rituximab | 0 | 1 |
Cyclophosphamide + Fludarabine + FT522 + Rituximab | Cyclophosphamide FT522 Fludarabine Rituximab | 0 | 1 |
FT522 | FT522 | 0 | 0 |
FT522 + Rituximab | FT522 Rituximab | 0 | 1 |